Cancer Cytotoxic Exosome Formulations and Methods for Use in Treating Cancer
By using metal sulfides (e.g., FeS2, CuS, CuS, and CuS) to adsorb and convert Hg0 from β-glucan-stimulated exosomes from human or animal cells, the challenges of existing technologies are addressed, achieving efficient and cost-effective mercury removal.
US20260000709A1Pending Publication Date: 2026-01-01JJR&D LLC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- US19/323475
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Priority Date
- 2022-11-23
- Filing Date
- 2025-09-09
- Publication Date
- 2026-01-01
Smart Images
Figure US20260000709A1-D00000_ABST
Abstract
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.
Need to check novelty before this filing date? Find Prior Art